Abstracts tagged "rheumatoid arthritis (RA) and sex bias"

Abstract Number: 1496 • 2018 ACR/ARHP Annual Meeting
Sex Differences in the Achievement of Clinical Remission and Low MRI Synovitis Scores in Rheumatoid Arthritis
Joshua Baker¹, Mikkel Østergaard², Carson Maynard³, Michael D. George⁴, Daniel Baker⁵ and Philip G. Conaghan⁶, ¹Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, ²Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup Copenhagen Center for Arthritis Research, Copenhagen, Denmark, ³Rheumatology, University of Pennsylvania, Philadlphia, PA, ⁴Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁵Johnson & Johnson, Spring House, PA, ⁶University of Leeds, Leeds, UK, Leeds, United Kingdom
Background/Purpose: Several prior studies have demonstrated poor clinical responses and reduced likelihood of achievement of remission among women with rheumatoid arthritis (RA). We aimed to…
Abstract Number: 165 • 2017 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Risk Polymorphisms in CCR6, SNP and Estrogen-Dependent Response to Immune Mediator Gene Expression, and NF-κb Transcriptional Activity: Crosstalk between the Immune and Endocrine Systems
Ming-Fen Ho¹, Tim Bongartz², James N. Ingle³, Liewei Wang¹ and Richard M. Weinshilboum¹, ¹Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, ²Emergency Medicine, Vanderbilt University, Nashville, TN, ³Department of Medical Oncology, Mayo Clinic, Rochester, MN
Background/Purpose: The rheumatoid arthritis (RA) risk locus CCR6 rs3093024 SNP is associated with increased risk of RA in a sex-specific pattern in Asian populations. Specifically,…
Abstract Number: 2388 • 2017 ACR/ARHP Annual Meeting
Women and Men with Rheumatoid Arthritis Present with Different Risks for Glucocorticoid-Related Comorbidities
Dörte Huscher¹, Katinka Albrecht¹, Frank Buttgereit², Thorsten Eidner³, Stefan Kleinert⁴, Wolfgang Ochs⁵ and Angela Zink⁶, ¹Epidemiology Unit, German Rheumatism Research Centre (DRFZ), Berlin, Germany, ²Department of Rheumatology and Clinical Immunology, Charité Univeris, Berlin, Germany, ³Rheumatology/ Osteology, Friedrich-Schiller-University Jena, University Clinic, Jena, Germany, ⁴Rheumatologie, Praxisgemeinschaft Rheumatologie-Nephrologie, Rheumatologische Schwerpunktpraxis, Erlangen, Germany, ⁵Internistisch-rheumatologische Praxisgemeinschaft Bayreuth, Bayreuth, Germany, ⁶Epidemiology Unit / Rheumatology and Clinical Immunology, German Rheumatism Research Centre (DRFZ) / Charité University Hospital, Berlin, Germany
Background/Purpose: Osteoporosis, diabetes, hypertension and cardiovascular diseases are the most threatening glucocorticoid (GC)-related comorbidities in rheumatoid arthritis (RA), both from the patients and rheumatologists perspective1.…
Abstract Number: 466 • 2016 ACR/ARHP Annual Meeting
Sexually Dimorphic Dysbiosis of Gut Microbiota in Tumor Necrosis Factor Transgenic Mice with Inflammatory-Erosive Arthritis
Richard Bell^1,2, Ronald Wood³, Christopher T. Ritchlin⁴, Edward Schwarz⁵ and Homaira Rahimi⁶, ¹Center for Musculoskelatal Research, University of Rochester, Rochester, NY, ²Pathology, University of Rochester, Rochester, NY, ³University of Rochester, Rochester, NY, ⁴Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁵Orthopedeatrics, University of Rochester, Rochester, NY, ⁶Rheumatology, University of Rochester/Golisano Children's Hosp, Rochester, NY
Background/Purpose: Recent studies identify gut microbiota dysbiosis as a possible contributor to rheumatoid arthritis (RA) pathogenesis. RA patients have significantly different microbiomes than healthy controls.…
Abstract Number: 514 • 2016 ACR/ARHP Annual Meeting
Gender Difference Is Apparent in the Risk of Forefoot Deformity in Patients with Rheumatoid Arthritis
Kentaro Inui¹, Tatsuya Koike², Tadashi Okano¹, Kenji Mamoto³, Kazuki Orita¹, Yuko Sugioka⁴, Masahiro Tada⁵, Hiroaki Nakamura³ and Orita incl, ¹Orthopaedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ²Center for Senile Degenerative Disorders, Osaka City University Medical School, Osaka, Japan, ³Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ⁴Center for Senile Degenerative Disorders (CSDD), Osaka City University Medical School, Osaka, Japan, ⁵Orthopedic Surgery, Osaka City General Hospital, Osaka, Japan
Background/Purpose: Forefoot involvement in patients with rheumatoid arthritis (RA) is common, and reported to be present in 50–90% of patients without any clear gender predisposition.…
Abstract Number: 1457 • 2016 ACR/ARHP Annual Meeting
Early Onset Morbidity and Mortality in Female Tumor Necrosis Factor Transgenic Mice with Inflammatory-Erosive Arthritis and Interstitial Lung Disease
Richard Bell¹, Emily Wu², Ronald Wood³, Joe Chakkalakal², Javier Rangel-Moreno⁴, Maria de la Luz Garcia-Hernandez², Christopher T. Ritchlin⁵, Edward Schwarz⁶ and Homaira Rahimi⁷, ¹Center for Musculoskelatal Research, University of Rochester, Rochester, NY, ²University of Rochaester, Rochester, NY, ³University of Rochester, Rochester, NY, ⁴Allergy, Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁵Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁶Orthopedeatrics, University of Rochester, Rochester, NY, ⁷Rheumatology, University of Rochester/Golisano Children's Hosp, Rochester, NY
Background/Purpose: Although exacerbated morbidity and mortality in rheumatoid arthritis (RA) is frequently seen in women, the etiology of this sexual dimorphism remains unclear. Previously, we…
Abstract Number: 2812 • 2014 ACR/ARHP Annual Meeting
Is Rheumatoid Arthritis the Same Disease in Women and Men?- Joint Damage in Patients with EARLY Rheumatoid Arthritis at 10 YEARS after Diagnosis
Juha Asikainen¹, Kalevi Kaarela², Heidi Mäkinen³, Hannu Kautiainen⁴, Pekka Hannonen⁵, Tuomas Rannio⁶ and Tuulikki Sokka⁷, ¹Jyvaskyla Central Hospital, Jyväskylä, Finland, ²Jyväskylä Central Hospital, Jyväskylä, Finland, ³Tampere University Hospital, Tampere, Finland, ⁴Medcare Oy, Äänekoski, Finland, ⁵Jyväskylä Central Hospital, Jyvaskyla, Finland, ⁶Kuopio University Hospital, Kuopio, Finland, ⁷Jyvaskyla Central Hospital, Jyvaskyla, Finland
Background/Purpose: Rheumatoid arthritis (RA) is suggested to be a more severe disease in women than in men as disease activity appears higher in women, and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].